In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection

SMT19969 [2,2′-bis(4-pyridyl)3H,3′-H 5,5-bibenzimidazole] is a novel narrow-spectrum nonabsorbable antibiotic currently in development for the treatment of Clostridium difficile infection. The comparative activities of SMT19969 and vancomycin against nonepidemic and epidemic strains of C. difficile...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, William, Pulse, Mark, Vickers, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2014
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187990/
https://www.ncbi.nlm.nih.gov/pubmed/25022586
http://dx.doi.org/10.1128/AAC.02903-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187990/
https://www.ncbi.nlm.nih.gov/pubmed/25022586
http://dx.doi.org/10.1128/AAC.02903-14

Ejemplares similares